Merus Merus N.V. announced planned changes to its Board of Directors. Dr. Anand Mehra will succeed Dr. Russell Greig as chairman of the board of directors from the conclusion of the company's AGM when Dr. Greig will be stepping down from the board of directors. Mr. Paolo Pucci has been nominated for appointment to the Company's Board of Directors at the upcoming AGM as Dr. John de Koning plans to step down at that time. Dr. Mehra has been a member of the Board of Directors since August 2015. He most recently served as General Partner at Sofinnova Investments Inc., a biotech investment firm, which he joined in 2007. Previously, Dr. Mehra worked in J.P. Morgan's private equity and venture capital group, and was a consultant in McKinsey & Company's pharmaceutical practice. Mr. Paolo Pucci most recently served as the Chief Executive Officer of ArQule Inc., a biopharmaceutical oncology and rare diseases company that was acquired by Merck in January 2020.

The company also announced that after having previously closed its research laboratories due to the COVID-19 pandemic, the company has reopened the Utrecht- based labs in compliance with The Netherlands guidelines and is restarting laboratory research activities.